No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 34 of the 36 quarters in the window, leaving 2 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 37
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:34.960Z. Latest historical point 2025-08-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T21:47:34.960Z. Latest historical point 2025-03-24.
The latest delayed quote for Neurogene Inc. (NGNE) stock was $25.45 as of Oct 6, 2026, 4:00 PM EDT, down 3.85% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +18.4% · 3-year avg +18.2%/yr · 5-year avg -27.7%/yr
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions.
Biotechnology · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-1.33
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.53
vs Estimate
$-1.42
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NGNE | $402.17M | $25.45 | -3.85% | +18.39% | -27.73% | -21.02% | N/A |
| 2MYGN | $404.24M | $4.28 | -6.55% | -43.02% | -32.02% | -14.20% | vs NGNE |
| 3AVIR | $405.74M | $5.07 | -1.17% | +76.42% | -34.44% | N/A | vs NGNE |
| 4CARL | $397.99M | $14.64 | -4.31% | +17.87% | N/A | N/A | vs NGNE |
| 5EIKN | $406.58M | $7.51 | -0.40% | N/A | N/A | N/A | vs NGNE |
| 6SI | $396.93M | $19.14 | -2.35% | +60.42% | N/A | N/A | vs NGNE |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$80.43
+216.0% upside
Low
$46.00
Current
$25.45
High
$166.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.53 | $-1.33 | $-1.23 | 4 |
| Quarter ending Dec 2026 | $-1.46 | $-1.32 | $-1.11 | 4 |
| Quarter ending Mar 2027 | $-1.31 | $-1.31 | $-1.31 | 1 |
| Quarter ending Jun 2027 | $-1.29 | $-1.29 | $-1.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.94 | $-5.57 | $-5.22 | 5 |
| FY 2027 | $-7.22 | $-5.41 | $-4.31 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $462500.00 | $462500.00 | $462500.00 | 7 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
